Sucampo Pharmaceuticals Inc. (SCMP) announced that it has closed enrollment and initial dosing of patients in two pivotal phase 3 trials of lubiprostone for the treatment of Opioid-Induced Bowel Dysfunction or OBD.
The OBD Pivotal Assessment of Lubiprostone program is designed to evaluate the effect of lubiprostone as a treatment for chronic pain patients suffering from constipation and associated symptoms as a result of chronic opioid therapy. Constipation and associated symptoms are a common side effect of the use of narcotic medications, such as morphine, codeine and hydrocodone, which are prescribed for chronic pain management. A total of 875 patients diagnosed with OBD were enrolled at 187 sites in the US and Canada. Patients will receive one 24-mcg gel capsule of lubiprostone twice a day or placebo for 12 weeks. The primary endpoint of the trial is the change from baseline in the frequency of spontaneous bowel movements at week 8.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.